Is APGE a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The AbbVie cash price was the final outcome, with revenue at None. Apogee was pre-commercial with no approved products. The bear case rests on for former APGE holders the main open items are administrative rather than market risks. Analysts covering it are spread from $133.00 to $135.11, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. For former APGE holders the main open items are administrative rather than market risks. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $133.00, -1.5% from the $135.07 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The AbbVie cash price was the final outcome. AbbVie paid $135.11 a share in cash, a fixed number with no equity component and no publicly disclosed contingent value right. The most optimistic analyst target on APGE is $135.11, +0.0% from the $135.07 price. That figure is only reachable if this thesis works close to its best case.

For former APGE holders the main open items are administrative rather than market risks. The cash conversion is generally a taxable disposition in a taxable account, with gain or loss measured against each holder's cost basis, which is worth discussing with a tax professional. Shares held in certificated or unusual form may need paperwork with the paying agent to collect the $135.11. Several plaintiffs' firms announced routine merger-adequacy and disclosure investigations around the deal, which are common in transactions of this size and are distinct from securities fraud class actions; none was identified as having changed the deal terms. For anyone weighing AbbVie as the way to keep exposure, the drug-level risks carry over: zumilokibart still has to succeed in Phase 3 and win share in an atopic dermatitis market led by Dupixent, and AbbVie's own guidance pushes the accretion it expects from the deal out to 2032. The most pessimistic published target is $133.00, -1.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Apogee Therapeutics engineers half-life-extended antibodies so that atopic dermatitis and asthma biologics can be dosed quarterly rather than fortnightly.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The AbbVie cash price was the final outcome) stalling in the reported numbers rather than in the narrative, the risk above (for former APGE holders the main open items are administrative rather than market risks) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Apogee was a clinical-stage biotech in Waltham, Massachusetts, founded in 2022 and public from July 2023 until its acquisition by AbbVie in September 2026, with roughly 261 employees and no product revenue. It engineered antibodies against already-validated inflammation targets so they last much longer in the body, aiming to replace injections every two weeks with quarterly or less frequent dosing. Its lead candidate is zumilokibart (APG777), an anti-IL-13 antibody for atopic dermatitis, now an AbbVie program.

It has been. On June 22, 2026 AbbVie announced an agreement, signed June 18, to acquire Apogee for $135.11 per share in cash, valuing the company at approximately $10.9 billion in total equity value. The one-step merger went to a shareholder vote at a virtual special meeting on August 11, 2026, and on September 3, 2026 Apogee filed an 8-K reporting completion of the acquisition along with a Nasdaq notice delisting the shares. AbbVie has said it expects the transaction to be accretive to adjusted diluted EPS beginning in 2032.

It no longer trades at all. While the deal was pending, the small gap below $135.11 was the merger spread, the market's price for waiting on the vote and regulatory clearance plus a small chance the deal failed. That gap had narrowed to four cents by the final close of $135.07 on September 2, 2026, and the shares were then converted to cash and removed from Nasdaq.